• The efficacy and safety of apixaban in patients with body weight ≥120 kg or BMI >40 kg/m2 were consistent with
    the main results of the AMPLIFY trial
  • Across body weight and BMI categories, compared with enoxaparin/warfarin, apixaban had:
    • Similar rates of recurrent VTE or VTE-related death
    • Lower rates of major bleeding (significant for body weight >60 to <100 kg and BMI >35 to 40 kg/m2 groups)
    • Lower rates of the composite of major or CRNM bleeding (significant for all groups)
  • No clinically meaningful differences in apixaban exposure between high and low body weight groups
  • The findings of this post hoc analysis support the use of apixaban in patients with body weight ≥120 kg or
    BMI >40 kg/m2
    • Prospective studies evaluating the efficacy and safety of apixaban for VTE treatment in obese patients with
      body weight ≥120 kg or BMI >40 kg/m2 are needed to confirm these findings